Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.

Abstract

Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angiogenesis, tumor proliferation, spread, and metastasis, but also to its immunomodulatory properties that have favorable effects on the very intricate role that the tumor microenvironment plays in carcinogenesis and tumor growth. In this review, we discuss rationale and evidence supporting regorafenib efficacy in HCC and that led to its approval as a second-line treatment, after sorafenib failure. We also discuss the evidence from clinical practice studies that confirm the results previously achieved in clinical trials. Finally, we analyze the potential role of regorafenib in emerging combined treatment approach with immunotherapy strategies using immune checkpoint blockade and its potential extension to patient categories not included in the registrative study.

• Authors: Alessandro Granito, Sara Marinelli, Antonella Forgione, Matteo Renzulli, Francesca Benevento, Fabio Piscaglia, Francesco Tovoli
• Journal: Journal of hepatocellular carcinoma (J Hepatocell Carcinoma) Vol. 8 Pg. 477-492 ( 2021) ISSN: 2253-5969 [Print] New Zealand
• PMID: 34079777 (Publication Type: Journal Article, Review)
• Copyright: © 2021 Granito et al.